La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach.

Identifieur interne : 001258 ( Main/Exploration ); précédent : 001257; suivant : 001259

Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach.

Auteurs : Darcy Litteljohn [Canada] ; Shawn Hayley

Source :

RBID : pubmed:22933144

English descriptors

Abstract

Cytokines, which are immunological messengers facilitating both intra- and inter-system communication, are considered central players in the neuroinflammatory cascades associated with the neurodegenerative process in Parkinson's disease (PD) and other neurological disorders. They have also been implicated in depression and other cognitive (e.g., memory impairment, dementia) and affective disturbances (e.g., anxiety) that show high co-morbidity with neurodegenerative diseases. As such, cytokines may hold great promise as serological biomarkers in PD, with potential applications ranging from early diagnosis and disease staging, to prognosis, drug discovery, and tracking the response to treatment. Subclassification or risk stratification in PD could be based (among other things) on reliably determined cytokine panel profiles or "signatures" of particular co-morbid disease states or at-risk groups (e.g., PD alone, PD with depression and/or dementia). Researchers and clinicians seeking to describe cytokine variations in health vs. disease will benefit greatly from technologies that allow a high degree of multiplexing and thus permit the simultaneous determination of a large roster of cytokines in single small-volume samples. The need for such highly paralleled assays is underscored by the fact that cytokines do not act in isolation but rather against a backdrop of complementary and antagonistic cytokine effects; ascribing valence to the actions of any one cytokine thus requires specific knowledge about the larger cytokine milieu. This chapter provides a technological overview of the major cytokine multiplex assay platforms before discussing the implications of such tools for biomarker discovery and related applications in PD and its depressive and cognitive co-morbidities.

DOI: 10.1007/978-1-62703-071-7_7
PubMed: 22933144


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach.</title>
<author>
<name sortKey="Litteljohn, Darcy" sort="Litteljohn, Darcy" uniqKey="Litteljohn D" first="Darcy" last="Litteljohn">Darcy Litteljohn</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neuroscience, Carleton University, Ottawa, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Neuroscience, Carleton University, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Hayley, Shawn" sort="Hayley, Shawn" uniqKey="Hayley S" first="Shawn" last="Hayley">Shawn Hayley</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22933144</idno>
<idno type="pmid">22933144</idno>
<idno type="doi">10.1007/978-1-62703-071-7_7</idno>
<idno type="wicri:Area/PubMed/Corpus">000B33</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B33</idno>
<idno type="wicri:Area/PubMed/Curation">000B33</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B33</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B33</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B33</idno>
<idno type="wicri:Area/Ncbi/Merge">001235</idno>
<idno type="wicri:Area/Ncbi/Curation">001235</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001235</idno>
<idno type="wicri:Area/Main/Merge">001286</idno>
<idno type="wicri:Area/Main/Curation">001258</idno>
<idno type="wicri:Area/Main/Exploration">001258</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach.</title>
<author>
<name sortKey="Litteljohn, Darcy" sort="Litteljohn, Darcy" uniqKey="Litteljohn D" first="Darcy" last="Litteljohn">Darcy Litteljohn</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neuroscience, Carleton University, Ottawa, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Neuroscience, Carleton University, Ottawa, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Hayley, Shawn" sort="Hayley, Shawn" uniqKey="Hayley S" first="Shawn" last="Hayley">Shawn Hayley</name>
</author>
</analytic>
<series>
<title level="j">Methods in molecular biology (Clifton, N.J.)</title>
<idno type="eISSN">1940-6029</idno>
<imprint>
<date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Biomarkers (analysis)</term>
<term>Comorbidity</term>
<term>Cytokines (analysis)</term>
<term>Cytokines (immunology)</term>
<term>Depressive Disorder (epidemiology)</term>
<term>Depressive Disorder (immunology)</term>
<term>Humans</term>
<term>Immunologic Techniques (instrumentation)</term>
<term>Immunologic Techniques (methods)</term>
<term>Inflammation (immunology)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson Disease (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>Biomarkers</term>
<term>Cytokines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Depressive Disorder</term>
<term>Inflammation</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="instrumentation" xml:lang="en">
<term>Immunologic Techniques</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Immunologic Techniques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Comorbidity</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Cytokines, which are immunological messengers facilitating both intra- and inter-system communication, are considered central players in the neuroinflammatory cascades associated with the neurodegenerative process in Parkinson's disease (PD) and other neurological disorders. They have also been implicated in depression and other cognitive (e.g., memory impairment, dementia) and affective disturbances (e.g., anxiety) that show high co-morbidity with neurodegenerative diseases. As such, cytokines may hold great promise as serological biomarkers in PD, with potential applications ranging from early diagnosis and disease staging, to prognosis, drug discovery, and tracking the response to treatment. Subclassification or risk stratification in PD could be based (among other things) on reliably determined cytokine panel profiles or "signatures" of particular co-morbid disease states or at-risk groups (e.g., PD alone, PD with depression and/or dementia). Researchers and clinicians seeking to describe cytokine variations in health vs. disease will benefit greatly from technologies that allow a high degree of multiplexing and thus permit the simultaneous determination of a large roster of cytokines in single small-volume samples. The need for such highly paralleled assays is underscored by the fact that cytokines do not act in isolation but rather against a backdrop of complementary and antagonistic cytokine effects; ascribing valence to the actions of any one cytokine thus requires specific knowledge about the larger cytokine milieu. This chapter provides a technological overview of the major cytokine multiplex assay platforms before discussing the implications of such tools for biomarker discovery and related applications in PD and its depressive and cognitive co-morbidities.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Hayley, Shawn" sort="Hayley, Shawn" uniqKey="Hayley S" first="Shawn" last="Hayley">Shawn Hayley</name>
</noCountry>
<country name="Canada">
<noRegion>
<name sortKey="Litteljohn, Darcy" sort="Litteljohn, Darcy" uniqKey="Litteljohn D" first="Darcy" last="Litteljohn">Darcy Litteljohn</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001258 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001258 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22933144
   |texte=   Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22933144" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022